Fate Therapeutics, Inc.
$2.52
$0.08 (+3.07%)
$2.46Day Range$2.56
Key Statistics
Market Cap
$292.36M
Shares Outstanding
119.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 1, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$2.48
Day High
$2.56
Day Low
$2.46
Volume
964.4K
VWAP
$2.52
Prev Close
$2.44
Transactions
--
Acc. Volume
--
About Fate Therapeutics, Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836161 employees12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131858.875.1803IPO Oct 1, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001434316
- Composite FIGI
- BBG000QP35H2
- Share Class FIGI
- BBG001T888S2
- Ticker Root
- FATE
- SIC Code
- 2836
About Fate Therapeutics, Inc. (FATE) Stock
Fate Therapeutics, Inc. (FATE) closed the 2026-09-17 session at $2.52, up 3.07% versus the previous close (+0.08). The stock opened at $2.48 and traded between $2.46 and $2.56 during that session. Session trading volume was 964K shares. The volume-weighted average price (VWAP) is $2.52.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics, Inc. has a market capitalization of $292.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. FATE is listed on the XNAS exchange. The company employs approximately 161 people. Fate Therapeutics, Inc. is headquartered in SAN DIEGO, CA. The recorded listing date is 2013-10-01.
On this page you can find market FATE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.